In This Section      
 

J. Bill McEvoy, MB BCh, MHS

Ciccarone Center Research

Published By

J. Bill McEvoy, MB BCh, MHS

J. Bill McEvoy, MB BCh, MHS
McEvoy, J. Bill, MB BCH, MHS

J. Bill McEvoy, MB BCH, MHS, is an Assistant Professor of Medicine.

Landmark Articles

Utility of coronary artery calcium scoring in the evaluation of patients with chest pain.

By: Tota-Maharaj R, McEvoy JW, Blaha MJ, Silverman MG, Nasir K, Blumenthal RS.
Although further research is needed, carefully selected patients presenting to the emergency department with a normal electrocardiogram, normal cardiac biomarkers, and no CAC may be considered for early discharge without further testing.

Utility of coronary artery calcium scoring in the evaluation of patients with chest pain.

By: Tota-Maharaj R, McEvoy JW, Blaha MJ, Silverman MG, Nasir K, Blumenthal RS.
Although further research is needed, carefully selected patients presenting to the emergency department with chest pain and with a normal electrocardiogram, normal cardiac biomarkers, and CAC = 0 may be considered for early discharge without further testing.

Rhinotillexis: a possible heuristic to reduce inappropriate noninvasive cardiac imaging?

Coronary artery calcium for the prediction of mortality in young adults <45 years old and elderly adults >75 years old.

By: Tota-Maharaj R, Blaha MJ, McEvoy JW, Blumenthal RS, Muse ED, Budoff MJ, Shaw LJ, Berman DS, Rana JS, Rumberger J, Callister T, Rivera J, Agatston A, Nasir K.
The value of coronary artery calcium for predicting mortality extends to both elderly patients and those <45 years old. Elderly persons with no CAC have a lower mortality rate than younger persons with high CAC.

Lifetime risks of cardiovascular disease.

Potential use of coronary artery calcium progression to guide the management of patients at risk for coronary artery disease events.

By: McEvoy JW, Blaha MJ, Nasir K, Blumenthal RS, Jones SR.
We believe that the data argues against the use of CAC progression as a clinical surrogate marker of preventive therapy efficacy. Further studies with non-statin medications and with concomitant outcome data are needed. However, CAC progression has potential for monitoring subclinical coronary artery disease (CAD) in some patients with mild CAC and may facilitate treatment decisions. In this review we provide recommendations for repeat CAC testing and discuss when repeat CAC testing may be helpful to assess CAD progression.

Potential use of coronary artery calcium progression to guide therapy and management of patients at risk for coronary artery disease.

By: McEvoy JW, Blaha MJ, Blumenthal RS, Jones SR, Nasir K.
This review examines the strengths and limitations of the existing data purporting to show an incremental prognostic benefit of looking at progression of CAC.

Statin therapy dose and risk of new-onset diabetes.

Impact of coronary computed tomographic angiography results on patient and physician behavior in a low-risk population.

By: McEvoy JW, Blaha MJ, Nasir K, Yoon YE, Choi EK, Cho IS, Chun EJ, Choi SI, Rivera JJ, Blumenthal RS, Chang HJ.
We studied asymptomatic patients from a large health-screening program. Our study population comprised 1,000 patients who underwent coronary CT angiography (CCTA) as part of a prior study and a matched control group of 1,000 patients who did not. We assessed medication use, secondary test referrals, revascularizations, and cardiovascular events at 90 days and 18 months. An abnormal screening CCTA result was predictive of increased aspirin and statin use at 90 days and 18 months, although medication use lessened over time. Screening CCTA was associated with increased invasive testing, without any difference in events at 18 months. Screening CCTA in asymptomatic adults should NOT be considered a justifiable test at this time.

Calcium score reclassification: how should baseline risk be measured?

By: McEvoy JW, Nasir K, Blumenthal RS.
A coronary artery score measurement to reclassify persons to either a low or high risk category has implications for preventive therapy strategies for patients in the broad intermediate cardiac risk category that need to be tested in a prospective, randomized manner.